CS-121 vs Olezarsen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Familial Chylomicronemia Syndrome
Shared mechanism: APOC3 · full Familial Chylomicronemia Syndrome pipeline
CS-121
Developed by CorrectSequence Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07176923 (registry estimate)
No aligned efficacy figure on record for this race.
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals and partners
NCT04568434 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 66 patients with a rare disease. Of its two primary comparisons, olezarsen 80 mg lowered triglycerides significantly more than placebo at 6 months (p=0.0009), but olezarsen 50 mg did not (p=0.0775), so the primary result was only partly met.
Next expected readout: June 2027 · NCT05185843 (registry estimate)
Reported efficacy
Percent Change From Baseline in Fasting TG at Month 6: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. (mixed)
Result source: NCT04568434
Results for Familial Chylomicronemia Syndrome
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
CS-121: no structured comparison results are available for Familial Chylomicronemia Syndrome.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Severe Hypertriglyceridemia
Shared mechanism: APOC3 · full Severe Hypertriglyceridemia pipeline
CS-121
Developed by CorrectSequence Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT07657780 (registry estimate)
No aligned efficacy figure on record for this race.
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals and partners
NCT05079919 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial of 617 patients. Both tested doses of olezarsen produced large reductions in triglycerides, the physiological measure that defines this disease, compared with placebo, with strong statistical significance.
Next expected readout: March 2027 · NCT05681351 (registry estimate)
Reported efficacy
Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)
Result source: NCT05552326
Results for Severe Hypertriglyceridemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
CS-121: no structured comparison results are available for Severe Hypertriglyceridemia.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olezarsen
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
Available safety results
Olezarsen
| Dropout rate | 12.1%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result8.8%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —50 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result—80 mg NCT05355402 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 10.3%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result14%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 50 mg injection site erythema 13.8% (placebo 0%) fatigue 10.3% (placebo 2.6%) urinary tract infection 10.3% (placebo 15.4%) NCT05355402 · Phase 2 · registry result, not featured evidence show 1 more result80 mg covid-19 7% (placebo 5.1%) diabetes mellitus 7% (placebo 2.6%) acute sinusitis 5.3% (placebo 2.6%) NCT05355402 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CS-121's landscape · Olezarsen's landscape